Get started
Work

P77.04 PROPEL: A Phase 1/2 Trial of Bempegaldesleukin (NKTR-214) Plus Pembrolizumab in Lung Cancer and other Advanced Solid Tumors

Year: 2021
Type: conference-abstract
DOI: 10.1016/j.jtho.2021.01.1162
Authors: D.R. Spigel, D. Rodríguez-Abreu, F. Cappuzzo, V. Velcheti, A.K. Ganti, D. Johnson, R. Govindan, S. Antonia, B. Besse, M. Altan, M. Edelman, S. Ramalingam, E. Felip, S. Gadgeel, O. Juan-Vidal, A. Gupta, S. Currie, W. Lin, M. Tagliaferri, M. Reck
Institutions: Hospital Universitario Insular de Gran Canaria, NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, VA Nebraska Western Iowa Health Care System, University of Nebraska Medical Center, Ochsner Medical Center, Washington University in St. Louis, Duke University, Duke Cancer Institute, Institut Gustave Roussy, The University of Texas MD Anderson Cancer Center, Fox Chase Cancer Center, Emory University, Winship Cancer Institute, Vall d'Hebron Hospital Universitari, Henry Ford Hospital, Hospital Universitari i Politècnic La Fe, Nektar Therapeutics (United States), German Center for Lung Research, LungenClinic Grosshansdorf
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: bronze
OpenAlex ID: W3139153871
Cites:
Cited by: 1
Related to: 10